

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 June 2007 (07.06.2007)

PCT

(10) International Publication Number
WO 2007/062678 A1

(51) International Patent Classification:

C07D 231/12 (2006.01) **A61K 31/415** (2006.01)
C07D 401/04 (2006.01) **A61P 11/00** (2006.01)
A61K 31/4439 (2006.01)

Hoersholm (DK). **GRIMSTRUP, Marie** [NO/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2790 Hoersholm (DK).

(74) Agent: **WALLS, Alan, James**; PO Box 223, Tadworth, Surrey KT20 5YF (GB).

(21) International Application Number:

PCT/EP2005/012881

(22) International Filing Date:

29 November 2005 (29.11.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant (for all designated States except US): **7TM PHARMA A/S** [DK/DK]; Fremtidsvej 3, DK-2790 Hoersholm (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ULVEN, Trond** [NO/DK]; Department of Chemistry, University of Southern Denmark, Campusvej 55, DK-5230 Odense (DK). **FRIMURER, Thomas** [DK/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2790 Hoersholm (DK). **RIST, Øystein** [NO/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2790 Hoersholm (DK). **KOSTENIS, Evi** [DE/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2790 Hoersholm (DK). **HÖGBERG, Thomas** [SE/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2790 Hoersholm (DK). **RECEVEUR, Jean-Marie** [FR/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2790

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHENOXYACETIC ACID DERIVATIVES AS CRTH2 RECEPTOR LIGANDS

(57) Abstract: 4-Bromo-2-[1-(3,5-dichloropyridin-2-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid, 4-bromo-2-[1-(3,5-dichloro-1-oxypyridin-4-yl)-1 H-pyrazole-4-carbonyl]-phenoxyacetic acid, 4-bromo-2[1 -(3,5-dichloro-2-hydroxypyridin-4-yl)-1 H-pyrazole-4-carbonyl]-phenoxyacetic acid, and {4cyclopropyl-2-[1-(2,6-dichloro-phenyl)-1 H-pyrazole-4-carbonyl]-phenoxy}-acetic acid and salts, hydrates and solvates thereof are ligands of the CRTH2 receptor, and of value for the treatment of, inter alia, asthma, rhinitis, allergic airway syndrome, or allergic rhinobronchitis.



WO 2007/062678 A1

PHENOXYACETIC ACID DERIVATIVES AS CRTH2 RECEPTOR LIGANDS


This invention relates to the use of a class of compounds which are ligands of the CRTH2 receptor (Chemoattractant Receptor-homologous molecule expressed on T Helper cells type 2), in the treatment of diseases responsive to modulation of CRTH2 receptor activity, principally diseases having a significant inflammatory component. The invention also relates to novel members of that class of ligands and pharmaceutical compositions containing them.

Many classes of antiinflammatory agents are known, including the non-steroidal antiinflammatory compounds known as NSAIDs and the inhibitors of cyclooxygenase (COX-1 and COX-2). Benzoylphenylacetic acid and some benzophenone derivatives with carboxymethoxy substituents in one of the rings have been identified as antiinflammatory agents (see, for example, Khanum et. al. Bioorganic Chemistry Vol 32, No. 4, 2004, pages 211-222 and the references cited therein). Some o-phenyl carbamoyl-phenoxyacetic acids and o-benzamido-phenoxyethyl tetrazoles have been reported as potential antiinflammatory agent, see for example Drain et. al. J. Pharm. Pharmac., 1971, 23, 857-864, and ibid 1970, 22, 684-693. WO 99/15520 discloses a few benzophenone derivatives with carboxymethoxy or tetrazolylmethoxy substituents in one of the rings, synthesised as members of a group of compounds said to have activity as inhibitors of peroxisome proliferator-activated receptor (PPAR), and utility in a variety of disease states including diabetes, cardiac disease, and circulatory disease.

The natural ligand of the G-protein coupled receptor CRTH2 is prostaglandin D2. As its name implies, CRTH2 is expressed on T helper cells type 2 (Th2 cells) but it is also known to be expressed on eosinophils and basophil cells. Cell activation as a result of binding of PGD2 to the CRTH2 receptor results in a complex biological response, including release of inflammatory mediators. Elevated levels of PGD2 are therefore associated with many diseases which have a strong inflammatory component, such as asthma, rhinitis and allergies. Blocking binding of PGD2 to the CRTH2 receptor is therefore a useful therapeutic strategy for treatment of such diseases.

Some small molecule ligands of CRTH2, apparently acting as antagonists of PGD2, are known, for example as proposed in the following patent publications: WO 03/097042, WO 03/097598, WO 03/066046, WO 03/066047, WO 03/101961, WO 03/101981, GB 2388540, WO 04/089885 and WO 05/018529.

Our copending international application PCT/EP2005/005884 is concerned with the use of a compound of formula (IA) or a salt, hydrate or solvate thereof in the manufacture of a composition for the treatment of disease responsive to modulation of CRTH2 receptor activity:



wherein

A represents a carboxyl group -COOH , or a carboxyl bioisostere;

A₁ is hydrogen or methyl;

ring Ar¹ is an optionally substituted phenyl ring or 5- or 6-membered monocyclic heteroaryl ring, in which $\text{AA}_1\text{CHO-}$ and **L2** are linked to adjacent ring atoms;

rings Ar², Ar³ each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted;

t is 0 or 1;

L2 and L3 each independently represents a divalent radical of formula $\text{-(Alk}^1\text{)}_m\text{-(Z)}_n\text{-(Alk}^2\text{)}_p$ wherein

m, n and p are independently 0 or 1,

Alk¹ and Alk² are independently optionally substituted straight or branched chain $\text{C}_1\text{-C}_3$ alkylene or $\text{C}_2\text{-C}_3$ alkenylene radicals which may contain a compatible -O- , -S- or -NR- link wherein R is hydrogen or $\text{C}_1\text{-C}_3$ alkyl, and

Z is -O- ; -S- ; -C(=O)- ; $\text{-SO}_2\text{-}$; -SO- ; -NR- ; $\text{-NRSO}_2\text{-}$; $\text{-SO}_2\text{NR-}$, -C(=O)NR- ; -NRC(=O)- ; -NRCONH- ; -NHCONR- ; -NRC(=NR)NH- ; -NHC(=NR)NR- ; -C(R)=N-NR- ; or -NR-N=C(R)- wherein R is hydrogen or $\text{C}_1\text{-C}_3$ alkyl; or a divalent 5- or 6-membered monocyclic carbocyclic or heterocyclic radical,

PROVIDED THAT

- (A) the total length of L2 and L3 does not exceed that of an unbranched saturated chain of 10 carbon atoms; and
- (B) L2 is not -C(=O)- , -C(=O)NR- , or -NRC(=O)- when Ar^2 is optionally substituted phenyl; and
- (C) (a) L2 is not a bond and (b) p in L2 is not 0 when n is 1 and Z is aryl or heteroaryl, and
- (D) (a) L2 is not -O- , $\text{-SO}_2\text{-}$, -NR- , $\text{-CHR}^{\text{X}}\text{R}^{\text{Y}}\text{-}$ or $\text{-CH(R}^{\text{X}}\text{)(OR}^{\text{Y}}\text{)-}$, wherein R^{X} and R^{Y} are independently hydrogen, halogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, or $\text{C}_3\text{-C}_7$ cycloalkyl, or join to form a ring, and (b) when p is 1 and n is 1 and Z is aryl or heteroaryl then Alk^2 is not $\text{-CHR}^{\text{X}}\text{R}^{\text{Y}}\text{-}$ or $\text{-CH(R}^{\text{X}}\text{)(OR}^{\text{Y}}\text{)-}$, wherein R^{X} and R^{Y} are independently hydrogen, halogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, or $\text{C}_3\text{-C}_7$ cycloalkyl, or join to form a ring.

This invention relates to certain compounds falling within the general ambit of, but not specifically disclosed in PCT/EP2005/005884, and which have the CRTH2 receptor activity and utilities described in that application.

According to the present invention, there is provided a compound selected from the group consisting of 4-bromo-2-[1-(3,5-dichloropyridin-2-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid, 4-bromo-2-[1-(3,5-dichloro-1-oxypyridin-4-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid, 4-bromo-2-[1-(3,5-dichloro-2-hydroxypyridin-4-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid, and {4-cyclopropyl-2-[1-(2,6-dichloro-phenyl)-1H-pyrazole-4-carbonyl]-phenoxy}-acetic acid and salts, hydrates and solvates thereof. Pharmaceutical compositions comprising a compound selected from the foregoing group together with a pharmaceutically acceptable carrier, also form part of the invention.

In a further aspect, the invention provides the use of a compound selected from the foregoing group in medicine, particularly in the manufacture of a medicament for treatment diseases responsive to modulation of CRTH2 receptor activity,

In another aspect, the invention provides a method of treatment of a subject suffering from a disease responsive to modulation of CRTH2 receptor activity, which comprised administering

to the subject an amount of a compound selected from the foregoing group effective to ameliorate the disease.

In particular, compounds with which the invention is concerned are useful in the treatment of disease associated with elevated levels of prostaglandin D2 (PGD2) or one or more active metabolites thereof.

Examples of such diseases include asthma, rhinitis, allergic airway syndrome, allergic rhinobronchitis, bronchitis, chronic obstructive pulmonary disease (COPD), nasal polyposis, sarcoidosis, farmer's lung, fibroid lung, cystic fibrosis, chronic cough, conjunctivitis, atopic dermatitis, Alzheimer's disease, amyotrophic lateral sclerosis, AIDS dementia complex, Huntington's disease, frontotemporal dementia, Lewy body dementia, vascular dementia, Guillain-Barre syndrome, chronic demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathy, multiple sclerosis, encephalomyelitis, panencephalitis, cerebellar degeneration and encephalomyelitis, CNS trauma, migraine, stroke, rheumatoid arthritis, ankylosing spondylitis, Behçet's Disease, bursitis, carpal tunnel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, dermatomyositis, Ehlers-Danlos Syndrome (EDS), fibromyalgia, myofascial pain, osteoarthritis (OA), osteonecrosis, psoriatic arthritis, Reiter's syndrome (reactive arthritis), sarcoidosis, scleroderma, Sjogren's Syndrome, soft tissue disease, Still's Disease, tendinitis, polyarteritis Nodosa, Wegener's Granulomatosis, myositis (polymyositis dermatomyositis), gout, atherosclerosis, lupus erythematosus, systemic lupus erythematosus (SLE), type I diabetes, nephritic syndrome, glomerulonephritis, acute and chronic renal failure, eosinophilia fascitis, hyper IgE syndrome, sepsis, septic shock, ischemic reperfusion injury in the heart, allograft rejection after transplantations, and graft versus host disease.

However, the compounds with which the invention is concerned are primarily of value for the treatment of asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis.

As used herein, the term "treatment" includes prophylactic treatment.

As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as ammonium hydroxide; alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline

tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like. Those compounds (I) which are basic can form salts, including pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, benzoic, benzenesulphonic, glutamic, lactic, and mandelic acids and the like.

Compositions

As mentioned above, the compounds with which the invention is concerned are capable of modulating CRTH2 activity, and are useful in the treatment of diseases which benefit from such modulation. Examples of such diseases are referred to above, and include asthma, allergy and rhinitis.

It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the pharmaceutical art.

The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. The orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats;

emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.

For topical application to the eye, the drug may be made up into a solution or suspension in a suitable sterile aqueous or non aqueous vehicle. Additives, for instance buffers such as sodium metabisulphite or disodium edeate; preservatives including bactericidal and fungicidal agents such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorhexidine, and thickening agents such as hypromellose may also be included.

The drug may also be formulated for inhalation, for example as a nasal spray, or dry powder or aerosol inhalers.

The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.

The compounds with which the invention is concerned may be administered alone, or as part of a combination therapy with other drugs used for treatment of diseases with a major inflammatory component. In the case of asthma, rhinitis, and allergic airway syndrome such drugs include corticosteroids, long-acting inhaled beta agonists, cromolyn, nedocromil, theophylline, leukotriene receptor antagonists, antihistamines, and anticholinergics (e.g. ipratropium), and are often administered as nasal sprays, dry powder or aerosol inhalers.


In the case of arthritis and related inflammatory diseases other known drugs include glucocorticoids, NSAIDs (Non Steroidal Anti-Inflammatory Drugs – conventional prostaglandin synthesis inhibitors, COX-2 inhibitors, salicylates), and DMARDs (disease-modifying anti-rheumatic drugs such as methotrexate, sulfasalazine, gold, cyclosporine).

Synthesis of compounds of the invention:General comments:


Microwave chemistry was performed in a Personal Chemistry Emrys Optimizer. NMR spectra were obtained on a Bruker Avance AMX 300 MHz instrument. LC/MS was performed on an Agilent 1100-series instrument. LC/MS methods are as follows:

Analytical an20p5: Column: Gemini 5 μ C18 2.0x50 mm; Flow: 1.2 mL/min; Gradient: 0-3.5 min: 10-95% MeCN in water, 3.5-4.5 min: 95% MeCN; Modifier: 5 mM ammonium formate; MS-ionisation mode: API-ES (pos.)

Analytical tfa20p5: Column: Gemini 5 μ C18 2.0x50 mm; Flow: 1.2 mL/min; Gradient: 0-3.5 min: 10-95% MeCN in water, 3.5-4.5 min: 95% MeCN; Modifier: 0.1% TFA; MS-ionisation mode: API-ES (pos.)

General Synthetic Route 1**Intermediate-1 (prepared by Step 1.1)**

Synthesis of pyrazole ring




(5-Bromo-2-hydroxyphenyl)-[1-(3,5-dichloropyridin-2-yl)-1H-pyrazol-4-yl]-methanone. To 6-bromo-3-formylchromone (126 mg, 0.5 mmol) in ethanol (1.5ml) in a reaction tube was added (3,5-dichloropyridin-2-yl)hydrazine (89 mg, 0.5 mmol) and the mixture was stirred over

night. 0.7 M KOH (0.75 mL, 0.53 mmol) was added to the mixture. The tube was sealed and heated by microwaves to 100 °C for 2 min. To the reaction mixture was added 3% HCl until pH ~1 and left to precipitate. The precipitate was filtered off and washed with a small amount of water and ethanol and concentrated to give the product (150 mg, 73%), which was used directly for the next step. LC-MS (an20p5): Rt 3.4 min, m/z 414 $[M + H]^+$.

Intermediate-2 (prepared by Step 1.2)


Alkylation of phenol



4-Bromo-2-[1-(3,5-dichloropyridin-2-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid ethyl ester. To intermediate-1 (132 mg, 0.32 mmol) in acetone (0.6 mL) was added ethyl bromoacetate (71 mg, 0.43 mmol, 1.3eq) and K_2CO_3 (50 mg, 0.361 mmol), and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was then concentrated in vacuo and the residue was partitioned between water and ethyl acetate. The organic phase was washed with brine, dried ($MgSO_4$) and concentrated to give the product (130 mg, 81%), which was used directly for the next step.

Example 1 - Compound D1 (prepared by Step 1.3)


4-Bromo-2-[1-(3,5-dichloropyridin-2-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid.



Hydrolysis of ester. To intermediate-2 (130 mg, 0.26 mmol) in THF (1.7 mL) was added $LiOH \cdot H_2O$ (35 mg, 0.83 mmol) in water (1.7 mL). The reaction mixture was stirred at room temperature for 1 h. Then 3% HCl was added until pH <1 and the mixture was extracted with DCM. The organic phase was dried ($MgSO_4$) and concentrated to give the product (106 mg, 86%).


LC/MS (an20p5): Rt 1.9 min, m/z 472 $[M + H]^+$; ^1H NMR (DMSO- d_6): δ 4.76 (s, 2H), 7.03 (d, J = 9.0 Hz, 1H), 7.55 (s, 1H), 7.66 (d, J = 9.0 Hz, 1H), 8.25 (s, 1H), 8.58 (s, 1H), 8.59 (s, 1H); 8.79 (s, 1H).

General Synthetic Route 2



Intermediate-3 (prepared by Step 2.1)


Formation of N-oxide



3,4,5-Trichloropyridine 1-oxide. A mixture of 3,4,5-trichloropyridine (1.82 g, 10 mmol) and methylrhenum(VII) trioxide (12.5mg, 0.05 mmol) in DCM (4 mL) was treated with 30% H₂O₂ (2 mL). The mixture was stirred for 48 h at 24 °C (water bath). Heptane was added to the reaction mixture and it was cooled to 0 °C. A precipitate was formed, which was filtered off and washed with cold heptane and a small amount of DCM. Finally the solid was dried to give the product (1.8 g, 90%). LC-MS (an20p5): Rt 0.8 min, *m/z* 198 [M + H]⁺.

Intermediate-4 (prepared by Step 2.2)


Formation of hydrazine



(3,5-Dichloro-1-oxypyridin-4-yl)hydrazine. A mixture of intermediate-3 (222 mg, 1.1 mmol) and hydrazine monohydrate (2 mL) was stirred for 2.5 h at room temperature. The precipitate was filtered and washed with EtOH and DCM and dried in vacuo at room temperature to give the product as a solid (590 mg, 92%). LC-MS (an20p5): Rt 0.4 min, m/z 194 $[M + H]^+$.

Intermediate-5 (prepared by Step 1.1)


Synthesis of pyrazole ring



(5-Bromo-2-hydroxyphenyl)-[1-(3,5-dichloro-1-oxypyridin-4-yl)-1H-pyrazol-4-yl]-methanone. To 6-bromo-3-formylchromone (380 mg, 1.5 mmol) in ethanol (4 mL) in a reaction tube was added the intermediate-4 (310 mg, 1.6 mmol) and the mixture was stirred over night. 0.9 M KOH (1.75 mL, 1.5 mmol) was added to the mixture. The mixture was stirred for 2h at room temperature and the reaction mixture was extracted with DCM. The organic phase was dried (MgSO_4) and concentrated to give the product (340 mg, 53 %). The product was used without further purification for the next step. LC-MS (tfa20p5): Rt 2.3 min, m/z 430 $[\text{M} + \text{H}]^+$.

Intermediate-6 (prepared by Step 1.2)


Alkylation of phenol



4-Bromo-2-[1-(3,5-dichloro-1-oxypyridin-4-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid ethyl ester. To intermediate-5 (322 mg, 0.75 mmol) in acetone (1.5 mL) was added ethyl bromoacetate (157 mg, 0.94 mmol) and K_2CO_3 (187 mg, 1.35 mmol), and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was then concentrated in vacuo and the residue was partitioned between water and EtOAc. The organic phase was washed with brine, dried (MgSO_4) and concentrated. Upon addition of a small amount of EtOAc the product precipitated out. Filtering and washing of the solid with EtOAc gave the product (273 mg, 70%). LC-MS (tfa20p5): Rt 2.4 min, m/z 516 $[\text{M} + \text{H}]^+$.


Example 2 - Compound D2 (prepared by Step 1.3)

4-bromo-2-[1-(3,5-dichloro-1-oxypyridin-4-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid,




Hydrolysis of ester: To intermediate-6 (116 mg, 0.23 mmol) in THF (0.35 mL) was added LiOH (10 mg, 0.24 mmol) in water (0.3 mL) and the mixture was stirred at room temperature for 1 h. Then 3% HCl was added until pH ~ 4-5 and the mixture was extracted with EtOAc. The organic phase was dried (MgSO₄) and concentrated to give the product (80 mg, 73%). LC/MS (tfa20p5): Rt 2.0 min, *m/z* 488 [M + H]⁺. ¹H NMR (DMSO-d₆): δ 4.61 (s, 2H), 6.99 (d, *J* = 9.0 Hz, 1H), 7.52 (s, 1H), 7.63 (d, *J* = 9.0 Hz, 1H), 8.33 (s, 1H), 8.85 (s, 2H), 8.89 (s, 1H).

General Synthetic Route 3



Example 3 - Compound D3 (prepared by Step 3.1)

4-Bromo-2-[1-(3,5-dichloro-2-hydroxypyridin-4-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid.



Conversion of N-oxide to 2-hydroxypyridine: To intermediate-6 (268 mg, 0.52 mmol) in THF (5.5 mL) was added Et₃N (0.37 mL) and trifluoroacetic anhydride (0.19 mL, 1.30 mmol) at 0 °C. The mixture was stirred at room temperature for 2.5 h. Then a solution of LiOH (163 mg, 3.9 mmol) in water (5.3 mL) was added and the mixture was stirred at room temperature for 1 h. Then 3% HCl was added until pH 4 and the mixture was extracted with EtOAc. The organic


phase was dried (MgSO_4) and concentrated to give the product (97 mg, 38%). LC/MS (tfa20p5): Rt 2.2 min, m/z 488 $[\text{M} + \text{H}]^+$. ^1H NMR (DMSO-d_6): δ 4.43 (s, 2H), 6.93 (d, $J = 8.9$ Hz, 1H), 7.48 (s, 1H), 7.59 (d, $J = 8.9$ Hz, 1H), 7.96 (s, 1H), 7.28 (s, 1H), 9.66 (s, 1H).

Example 4 – Compound D4

{4-Cyclopropyl-2-[1-(2,6-dichloro-phenyl)-1H-pyrazole-4-carbonyl]-phenoxy}-acetic acid

Step 1


{4-Bromo-2-[1-(2,6-dichloro-phenyl)-1H-pyrazole-4-carbonyl]-phenoxy}-acetic acid ethyl ester.



To 6-bromo-3-formylchromone and 2,6-dichlorophenylhydrazine (1.0 mmol) and 2,6-dichlorophenylhydrazine (1.0 mmol) in ethanol (3.0 mL) in a reaction tube was added 4 M aq. KOH (1.0 mL, 4.0 mmol). The tube was sealed and heated by microwaves to 120 °C for 7 min (420 s). The reaction mixture was added 3% HCl until pH <1 and left to precipitate. The precipitate was filtered off and washed with a small amount of ethanol. To the precipitate (0.5 mmol) in acetone (1 mL) was added ethyl bromoacetate (85 mg, 0.5 mmol) and K_2CO_3 (75 mg, 0.54 mmol), and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was then concentrated in vacuo and the residue was partitioned between water and ethyl acetate. The organic phase was washed with brine, dried (MgSO_4) and concentrated. The product was purified by recrystallization from MeOH.: Rt 3.10 min, m/z 498.9 $[\text{M} + \text{H}]^+$; ^1H NMR (CDCl_3): δ 1.25 (t, 3H), 4.20 (q, 2H), 4.65 (s, 2H), 6.72-6.75 (d, 1H), 7.4-7.6 (m, 4H), 7.65 (s, 1H), 8.18 (s, 1H), 8.26 (s, 1H).

Step 2

{4-Cyclopropyl-2-[1-(2,6-dichloro-phenyl)-1H-pyrazole-4-carbonyl]-phenoxy}-acetic acid



To a degassed mixture of {4-bromo-2-[1-(2,6-dichloro-phenyl)-1H-pyrazole-4-carbonyl]-phenoxy}-acetic acid ethyl ester (1.16mmol), cyclopropyl boronic acid (2.33 mmol), sat. aqueous sodium carbonate (1.8ml) in dry 1,4-dioxane (5ml) was added, under an argon atmosphere, 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium (II) (0.058mmol). The reaction mixture was stirred for 5 days at 90°C. After cooling, solid particles were filtered off and the filtrate was concentrated in vacuo. The residue was purified on a SAX-acetate column and/or by flash chromatography (CH₂Cl₂/MeOH/CH₃CO₂H: 90/9/1). The product is a 50:50 mixture of title compound and {4-bromo-2-[1-(2,6-dichloro-phenyl)-1H-pyrazole-4-carbonyl]-phenoxy}-acetic acid: LC/MS (tfa20p5): Rt 2.62 min, *m/z* 431.0 [M + H]⁺, from which the desired title product is separated by additional chromatography.




Biological data:

Compounds were tested in the receptor binding assay and the functional antagonist assay described below, and their IC₅₀ values were assessed. The compounds are grouped in three classes:

- A: IC₅₀ value lower than 0.5 μM
- B: IC₅₀ value between 0.5 μM and 5 μM
- C: IC₅₀ value higher than 5 μM

Table 1 gives the biological test results for the compounds D1-D3 synthesised above.

Table 1

Compound		Binding IC ₅₀	Antag. IC ₅₀
D1		A	A
D2		A	A
D3		A	A

Biological Assays

Materials and Methods

Generation/origin of the cDNA Constructs. The coding sequence of the human CRTH2 receptor (genbank accession no NM_004778) was amplified by PCR from a human hippocampus cDNA library and inserted into the pcDNA3.1(+) expression vector (invitrogen) via 5' HindIII and 3' EcoRI. To generate a CRTH2-Renilla luciferase (CRTH2-Rluc) fusion protein, the CRTH2 coding sequence without a STOP codon and Rluc were amplified, fused in frame by PCR and subcloned into the pcDNA3.1(+)Zeo expression vector (invitrogen). Human β -arrestin2 (β -arr2) N-terminally tagged with GFP² (β arr2-GFP²) and Renilla luciferase were purchased from BioSignal Packard Inc, (Montreal, Canada). The sequence identity of the construct was verified by restriction endonuclease digests and sequencing in both directions on an ABI Prism (Applied Biosystems, Foster City, CA).

Cell Culture and Transfection. COS-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) 1885 supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 1000 µg/ml streptomycin, and kept at 37°C in a 10% CO₂ atmosphere. HEK293 cells were maintained in Minimum Essential medium (MEM) supplemented with 10% (v/v) heat inactivated fetal calf serum (HIFCS), 2mM GlutamaxTM-I, 1% non essential amino acids (NEAA), 1% sodium pyruvate and 10 µg/ml gentamicin. For binding experiments, COS7 cells were transiently transfected with the CRTH2 receptor using a calcium phosphate-DNA coprecipitation method with the addition of chloroquine (as described by Holst et al., 2001+). To perform the functional Bioluminescence Resonance Energy Transfer (BRET) assays, a HEK293 cell clone stably expressing β arr2-GFP² and CRTH2-Rluc was generated (CRTH2-HEK293 cells).

Binding assay. 24h after transfection COS-7 cells were seeded into 96well plates at a density of 30.000 cells/well. Competition binding experiments on whole cells were then performed about 18-24 h later using 0.1 nM [³H]PGD2 (NEN, 172 Ci/mmol) in a binding buffer consisting of HBSS (GIBCO) and 10 mM HEPES. Competing ligands were diluted in DMSO which was kept constant at 1% (v/v) of the final incubation volume. Total and nonspecific binding were determined in the absence and presence of 10 µM PGD2. Binding reactions were routinely conducted for 3 h at 4°C and terminated by 2 washes (100 µl each) with ice cold binding buffer. Radioactivity was determined by liquid scintillation counting in a TOPCOUNTER (Packard) following over night incubation in Microscint 20. Stable HEK293 cells were seeded at a density of 30.000 cells/well 18-24 h prior to the binding assay which was performed essentially as described for COS7 cells above. Determinations were made in duplicates.

BRET assay. Functional BRET assays were performed on HEK293 cells stably expressing human CRTH2-Rluc and GFP²- β -arr2. Prior to their use in the BRET assay cells were detached and re-suspended in D-PBS with 1000 mg/L L-Glucose at a density of 2×10^6 cells/mL. DeepBlueCTM was diluted to 50 µM in D-PBS with 1000 mg/L L-Glucose (light sensitive). 100 µL of cell suspension was transferred to wells in a 96-well microplate (white OptiPlate) and placed in the Mithras LB 940 instrument (BERTHOLD TECHNOLOGIES, Bad Wildbad, Germany). 12 µL/well agonist was then injected by injector 1 and 10 µL/well DeepBlueCTM was injected simultaneously by injector 2. Five seconds after the injections the light output from the well was measured sequentially at 400 nm and 515 nm, and the BRET signal (mBRET ratio) was calculated by the ratio of the fluorescence emitted by GFP²- β -arr2 (515 nm) over the light emitted by the receptor-Rluc (400 nm). Antagonists were added before

placing the microplates into the Mithras LB 940 and allowed to incubate for 15 minutes prior to the addition of agonist and DeepBlueC™. Compounds were dissolved in DMSO and the final DMSO concentration was kept constant at 1% in the assay.

Claims:

1. A compound selected from 4-bromo-2-[1-(3,5-dichloropyridin-2-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid, 4-bromo-2-[1-(3,5-dichloro-1-oxypyridin-4-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid, 4-bromo-2-[1-(3,5-dichloro-2-hydroxypyridin-4-yl)-1H-pyrazole-4-carbonyl]-phenoxyacetic acid, and {4-cyclopropyl-2-[1-(2,6-dichloro-phenyl)-1H-pyrazole-4-carbonyl]-phenoxy}-acetic acid and salts, hydrates and solvates thereof.
2. A pharmaceutical composition comprising a compound as claimed in claim 1, together with a pharmaceutically acceptable carrier.
3. A compound as claimed in claim 1 for use in medicine.
4. The use of a compound as claimed in claim 1 in the manufacture of a medicament for treatment diseases responsive to modulation of CRTH2 receptor activity,
5. A method of treatment of a subject suffering from a disease responsive to modulation of CRTH2 receptor activity, which comprises administering to the subject an amount of a compound as claimed in claim 1 effective to ameliorate the disease.
6. The use as claimed in claim 4 or a method as claimed in claim 5 wherein the disease is asthma, rhinitis, allergic airway syndrome, allergic rhinobronchitis, bronchitis, chronic obstructive pulmonary disease (COPD), nasal polyposis, sarcoidosis, farmer's lung, fibroid lung, cystic fibrosis, chronic cough, conjunctivitis, atopic dermatitis, Alzheimer's disease, amyotrophic lateral sclerosis, AIDS dementia complex, Huntington's disease, frontotemporal dementia, Lewy body dementia, vascular dementia, Guillain-Barre syndrome, chronic demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathy, multiple sclerosis, encephalomyelitis, panencephalitis, cerebellar degeneration and encephalomyelitis, CNS trauma, migraine, stroke, rheumatoid arthritis, ankylosing spondylitis, Behçet's Disease, bursitis, carpal tunnel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, dermatomyositis, Ehlers-Danlos Syndrome (EDS), fibromyalgia, myofascial pain, osteoarthritis (OA), osteonecrosis, psoriatic arthritis, Reiter's syndrome (reactive arthritis), sarcoidosis, scleroderma, Sjogren's Syndrome, soft tissue disease, Still's Disease, tendinitis, polyarteritis Nodosa, Wegener's Granulomatosis, myositis (polymyositis dermatomyositis), gout, atherosclerosis, lupus erythematosus, systemic lupus erythematosus (SLE), type I diabetes, nephritic syndrome, glomerulonephritis, acute and chronic renal failure, eosinophilia

fascitis, hyper IgE syndrome, sepsis, septic shock, ischemic reperfusion injury in the heart, allograft rejection after transplantations, or graft versus host disease.

7. The use as claimed in claim 4 or a method as claimed in claim 5 wherein the disease is asthma, rhinitis, allergic airway syndrome, or allergic rhinobronchitis.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2005/012881

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D231/12 C07D401/04 A61K31/4439 A61K31/415 A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2005/018529 A (ASTRAZENECA AB; ASTRAZENECA UK LIMITED; BONNERT, ROGER, VICTOR; PATEL,) 3 March 2005 (2005-03-03) claims 1-5 page 1, lines 14-17	1-7
A	WO 2004/089884 A (ASTRAZENECA AB; PAIRAUDEAU, GARRY; RASUL, RUKHSANA; THOM, STEPHEN) 21 October 2004 (2004-10-21) claims 1-11 page 1, lines 3-15	1-7
E	WO 2005/115382 A (7TM PHARMA A/S; ULVEN, TROND; FRIMURER, THOMAS; RIST, OEYSTEIN; KOSTEN) 8 December 2005 (2005-12-08) cited in the application the whole document	1-7

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 March 2006

Date of mailing of the international search report

16/03/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Marzi, E

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2005/012881

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 5-7
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 5-7 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2005/012881

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2005018529	A	03-03-2005	NONE	
WO 2004089884	A	21-10-2004	NONE	
WO 2005115382	A	08-12-2005	NONE	